Are DOACs commonly used for clot treatment?
Direct Oral Anticoagulants (DOACs) are now the primary and most common treatment for blood clots, such as deep vein thrombosis (DVT) and pulmonary embolism (PE), in the UK. Since the update of NICE guideline NG158, medications like apixaban and rivaroxaban have replaced warfarin as the first-line therapy for the majority of patients. They are preferred due to their rapid onset of action, predictable dosing, and the fact that they do not require the frequent, lifelong blood monitoring tests associated with older anticoagulant therapies.
What We will cover in this Article
- The shift from warfarin to DOACs in standard NHS practice
- How DOACs work to prevent clot growth and recurrence
- The benefits of predictable dosing and no routine blood monitoring
- Common causes of blood clots requiring DOAC therapy
- Triggers and risk factors that influence the choice of medication
- Situations where DOACs may not be the appropriate choice
- Emergency safety guidance for patients on anticoagulation
The standard of care: Why DOACs are preferred
In modern UK clinical practice, DOACs which include apixaban, rivaroxaban, edoxaban, and dabigatran are the gold standard for treating venous thromboembolism. Unlike older medications that interfere with Vitamin K across multiple clotting factors, DOACs are highly targeted. They focus on inhibiting specific enzymes, such as Factor Xa or thrombin, which are essential for the formation of a stable blood clot. This precision allows for a more consistent effect on the blood, making them significantly easier for both patients and clinicians to manage.
For most patients diagnosed at a DVT clinic, treatment begins immediately with a DOAC. The convenience of taking a fixed-dose tablet once or twice a day, without having to worry about dietary restrictions or attending weekly blood test appointments (INR tests), has made DOACs the most common choice. Furthermore, large-scale studies have shown that DOACs are at least as effective as warfarin at preventing further clots while often carrying a lower risk of serious complications, such as bleeding in the brain.
How DOACs are administered
When you are prescribed a DOAC for a clot, the treatment usually starts with a loading dose. This means you take a higher dose for the first few days or weeks to ensure the blood is sufficiently anticoagulated while the clot is most unstable. For example, apixaban is often taken at a higher dose for seven days, while rivaroxaban requires a higher dose for twenty-one days. Following this initial period, you move to a lower, long-term maintenance dose.
It is vital to understand that DOACs have a relatively short half-life, meaning they leave the body much faster than warfarin. While this is an advantage if you need surgery, it means that missing even a single dose can leave you unprotected. Consistency is the most important factor when using these medications. Most patients will remain on this treatment for a minimum of three to six months, depending on the cause of their clot.
Causes of clots treated with DOACs
The reason a clot formed in the first place helps doctors determine how a DOAC should be used and for how long. DOACs are effective across a wide range of underlying causes, from genetic predispositions to physical changes in the body. By addressing the chemical balance of the blood, these medications provide a safety net while the body’s natural systems work to break down the obstruction in the vein.
Common causes include:
- Venous stasis: Sluggish blood flow often seen in patients with heart failure or chronic venous insufficiency.
- Endothelial damage: Irritation or injury to the vein wall from previous surgery or trauma.
- Hypercoagulability: A natural tendency for the blood to clot more easily, which can be linked to certain illnesses or inherited blood conditions.
- Malignancy: Some cancers change the blood’s chemistry, making anticoagulation a vital part of cancer care.
Triggers and lifestyle factors
Triggers are the temporary events that can provoke a clot, necessitating the use of a DOAC. Recognising these triggers is essential because if the trigger is removed, the patient may only need the medication for a few months. However, if the triggers are persistent or lifestyle-related, the clinician may recommend a longer course of treatment to prevent the condition from returning.
Key triggers include:
- Recent surgery: Particularly orthopaedic procedures on the lower limbs.
- Prolonged immobility: Long-haul travel, bed rest, or a sedentary lifestyle.
- Hormonal triggers: Use of the combined contraceptive pill or hormone replacement therapy (HRT).
- Dehydration and smoking: Both of which can negatively impact blood flow and vessel health.
Differentiation: When DOACs are not used
While DOACs are the most common treatment, they are not suitable for everyone. There are specific clinical situations where older treatments or injections are still required. Differentiating between these patient groups is a critical part of the assessment at any DVT or anticoagulation clinic to ensure the highest level of patient safety.
DOACs are typically avoided in:
- Patients with mechanical heart valves: Warfarin remains the only safe option here.
- Severe kidney disease: As DOACs are cleared by the kidneys, they can build up to dangerous levels if renal function is too low.
- Pregnancy and breastfeeding: DOACs can cross the placenta or enter breast milk; therefore, heparin injections are used instead.
- Antiphospholipid Syndrome (APS): A specific immune condition where warfarin has been shown to be more effective at preventing recurrent clots.
Conclusion
DOACs have revolutionised the way blood clots are treated in the UK, providing a safe, effective, and much more convenient alternative to older therapies. By targeting specific parts of the clotting process, they allow patients to recover from DVT and PE with minimal disruption to their daily lives. If you have been prescribed a DOAC, it is essential to take it exactly as directed to ensure your continued protection.
If you experience severe, sudden, or worsening symptoms, call 999 immediately.
‘Which DOAC is the best?’
There is no single ‘best’ DOAC; the choice depends on your kidney function, other medications you take, and whether you prefer a once-daily or twice-daily tablet.
‘Can I drink alcohol while taking a DOAC?’
Moderate alcohol consumption is usually fine, but heavy drinking should be avoided as it can increase your risk of falls and injury, which is more dangerous while on blood thinners.
‘Do I still need to have my blood checked?’
You do not need regular INR tests, but you will typically have a blood test once a year to check your kidney and liver function to ensure the dose is still correct.
‘What if I forget to take my tablet?’
You should check the leaflet for your specific medication, but generally, you should take it as soon as you remember unless it is nearly time for your next dose. Never double the dose.
‘Can I take herbal supplements with DOACs?’
Some supplements, such as St John’s Wort, can interfere with how DOACs work. Always check with your pharmacist before starting any new herbal remedy.
‘Will a DOAC make me bruise more?’
Yes, it is very common to notice more bruising or to bleed for longer if you cut yourself, as your blood’s ability to form a ‘plug’ is reduced.
‘Are DOACs expensive for the NHS?’
While the tablets themselves cost more than warfarin, they save the NHS money by reducing the need for thousands of clinic appointments and blood tests.
Authority Snapshot
This article reflects current UK clinical standards for the management of venous thromboembolism. It is based on the prescribing framework set out by NICE and the British National Formulary (BNF). The information provided aims to help patients understand why DOACs are the preferred treatment choice and how to use them safely. Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being.
